Abstract Library

#4230 Grade ≥3 subacute haematological toxicity with 177Lu-DOTATATE PRRT – Results from LUMEN study

Introduction: Bone marrow toxicity during peptide receptor radionuclide therapy (PRRT), results from radiation damage to haematopoietic tissue. Prospective comprehensive data on subacute haematological toxicity are scarce.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, van Bogaert C, Ameye L, Flamen P, Karfis I,

Keywords: peptide receptor radionuclide therapy, GEP-NET, haematological toxicity,

#3563 Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?

Introduction: Tumor dosimetry protocols following Peptide Receptor Radionuclide Therapy (PRRT) have not yet been standardised and tumor absorbed dose does not hold clear value in predicting response to treatment.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, Marin G, Levillain H, van Bogaert C, Critchi G,

Keywords: PRRT, tumor dose, 68Ga-DOTATATE, SUVmax, response,

#3516 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)

Introduction: 177Lu-PRRT became an established therapeutic modality in inoperable or metastatic NETs, demonstrating substantial survival benefits and reassuring safety profile. Dosimetry of Organs-At-Risk [OAR, kidneys, bone marrow (BM) and spleen] and malignant lesions ensures to further optimize its safety and efficacy.

Conference:

Presenting Author: van Bogaert C

Authors: van Bogaert C, Mileva M, Marin G, Levillain H, Artigas-Guix C,

Keywords: PRRT, Safety, Dosimetry, Prospective trial,